Inozyme Pharma Q3 EPS $(0.29) Beats $(0.32) Estimate
Portfolio Pulse from Benzinga Newsdesk
Inozyme Pharma reported Q3 losses of $(0.29) per share, beating the analyst consensus estimate of $(0.32) by 9.38 percent. This represents a 23.68 percent increase over losses from the same period last year.
November 07, 2023 | 1:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Inozyme Pharma's Q3 earnings beat estimates, showing a 23.68% improvement from last year.
Inozyme Pharma's Q3 earnings beat analyst estimates, which is generally seen as a positive sign by investors. The improvement from last year's losses also indicates that the company's financial situation is improving, which could lead to a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100